These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 24667460)

  • 21. Effects of glucagon-like peptide-1 on islet function and insulin sensitivity in noninsulin-dependent diabetes mellitus.
    Ahrén B; Larsson H; Holst JJ
    J Clin Endocrinol Metab; 1997 Feb; 82(2):473-8. PubMed ID: 9024239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
    Nauck MA; Heimesaat MM; Orskov C; Holst JJ; Ebert R; Creutzfeldt W
    J Clin Invest; 1993 Jan; 91(1):301-7. PubMed ID: 8423228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas.
    Gutniak MK; Juntti-Berggren L; Hellström PM; Guenifi A; Holst JJ; Efendic S
    Diabetes Care; 1996 Aug; 19(8):857-63. PubMed ID: 8842604
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
    Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
    Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes.
    Zander M; Taskiran M; Toft-Nielsen MB; Madsbad S; Holst JJ
    Diabetes Care; 2001 Apr; 24(4):720-5. PubMed ID: 11315837
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes.
    Farngren J; Persson M; Schweizer A; Foley JE; Ahrén B
    Diabetes Obes Metab; 2014 Sep; 16(9):812-8. PubMed ID: 24612221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus.
    Todd JF; Wilding JP; Edwards CM; Khan FA; Ghatei MA; Bloom SR
    Eur J Clin Invest; 1997 Jun; 27(6):533-6. PubMed ID: 9229235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action.
    Hare KJ; Vilsbøll T; Asmar M; Deacon CF; Knop FK; Holst JJ
    Diabetes; 2010 Jul; 59(7):1765-70. PubMed ID: 20150286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes.
    Bergmann NC; Gasbjerg LS; Heimbürger SM; Krogh LSL; Dela F; Hartmann B; Holst JJ; Jessen L; Christensen MB; Vilsbøll T; Lund A; Knop FK
    Diabetes Care; 2020 Mar; 43(3):588-596. PubMed ID: 31949084
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment.
    Larsen J; Hylleberg B; Ng K; Damsbo P
    Diabetes Care; 2001 Aug; 24(8):1416-21. PubMed ID: 11473079
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Addition of metformin to exogenous glucagon-like peptide-1 results in increased serum glucagon-like peptide-1 concentrations and greater glucose lowering in type 2 diabetes mellitus.
    Cuthbertson J; Patterson S; O'Harte FP; Bell PM
    Metabolism; 2011 Jan; 60(1):52-6. PubMed ID: 20152998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes.
    Mentis N; Vardarli I; Köthe LD; Holst JJ; Deacon CF; Theodorakis M; Meier JJ; Nauck MA
    Diabetes; 2011 Apr; 60(4):1270-6. PubMed ID: 21330636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucagon-like peptide 1 increases secretory burst mass of pulsatile insulin secretion in patients with type 2 diabetes and impaired glucose tolerance.
    Ritzel R; Schulte M; Pørksen N; Nauck MS; Holst JJ; Juhl C; März W; Schmitz O; Schmiegel WH; Nauck MA
    Diabetes; 2001 Apr; 50(4):776-84. PubMed ID: 11289042
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lixisenatide resensitizes the insulin-secretory response to intravenous glucose challenge in people with type 2 diabetes--a study in both people with type 2 diabetes and healthy subjects.
    Becker RH; Stechl J; Msihid J; Kapitza C
    Diabetes Obes Metab; 2014 Sep; 16(9):793-800. PubMed ID: 24521245
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
    Nauck MA; Weber I; Bach I; Richter S; Orskov C; Holst JJ; Schmiegel W
    Diabet Med; 1998 Nov; 15(11):937-45. PubMed ID: 9827848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
    Rachman J; Gribble FM; Barrow BA; Levy JC; Buchanan KD; Turner RC
    Diabetes; 1996 Nov; 45(11):1524-30. PubMed ID: 8866556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The insulinotropic effect of pulsatile compared with continuous intravenous delivery of GLP-1.
    Plummer MP; Kar P; Cousins CE; Lange K; Chapman MJ; Nauck MA; Horowitz M; Meier JJ; Deane AM
    Diabetologia; 2016 May; 59(5):966-9. PubMed ID: 26831299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucagon-like peptide-1 (7-37) augments insulin-mediated glucose uptake in elderly patients with diabetes.
    Meneilly GS; McIntosh CH; Pederson RA; Habener JF; Gingerich R; Egan JM; Elahi D
    J Gerontol A Biol Sci Med Sci; 2001 Nov; 56(11):M681-5. PubMed ID: 11682575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.
    Christensen MB
    Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.